Best-Performing ETF Areas of August
August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable
ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
Best ETF Areas of June
Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
COVID, Ukraine, ChatGPT Expose Thematic Fund Gaps
FactSet analysis shows thematic funds respond differently to market shocks, with some genomic ETFs rising after COVID while others lagged.
ARKG: Cathie Wood's Biotech Product Is In Rally Mode
ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% since July and beating the S&P 500 by 12 percentage points. The ETF's concentrated, small-cap, high-risk portfolio is supported by rising AUM, robust liquidity, and a bullish technical breakout.
Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again
It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Cathie Wood's Top Biotech Plays for February
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
